NCT05464784 - MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 22, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Diabetes Mellitus, Type 2HypertriglyceridemiaNon-Alcoholic Fatty Liver Disease

Interventions

DRUG

MN-001

MN-001 is a novel, orally bioavailable small molecule compound

DRUG

MN-001 placebo

The placebo tablet is identical in appearance to the MN-001 tablet, and contains excipients of MN-001.

Trial Locations (2)

RECRUITING

Pinnacle Clinical Research at South Texas Research Institute, Edinburg

RECRUITING

Jubilee Clinical Research, Inc., Las Vegas